<DOC>
	<DOCNO>NCT01250665</DOCNO>
	<brief_summary>This study cross sectional study patient diagnose clinically isolated syndrome ( CIS ) RRMS , undergo series test assess cognitive impairment , fatigue severity depressive symptom . Cognitive impairment assess Multiple Sclerosis Inventory Cognition ( MUSIC ) symbol digit modality test ( SDMT ) , fatigue severity measure Fatigue Scale Motor Cognitive Functions ( FSMC ) depressive symptom Beck Depression Inventory ( BDI ) . All test mention validated MS patient . In second step use large longitudinal database serial MRI examination linear measurement CCI retrospectively calculate .</brief_summary>
	<brief_title>Study Comparing Corpus Callosum Atrophy Marker Later Development Cognitive Impairment Patients With Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Patients 18 55 year presentation Diagnosis relapsingremitting MS accord revise McDonald criterion 2005 , clinically isolated syndrome suggestive MS Patients treat interferonbeta 1b Untreated patient EDSS 5.5 Brain pathology MS Known history head trauma Pure spinal manifestation demyelization Neuromyelitis optica Primary secondary progressive MS Benzodiazepine intake within last three month Relapse within last three month Steroid intake within last three month History severe depressive disorder and/or suicidality , seizure , drug alcohol abuse No inform consent Insufficient knowledge German</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>cognitive impairment</keyword>
	<keyword>interferon-beta 1b</keyword>
	<keyword>corpus callosum index</keyword>
</DOC>